Journal
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
Volume 28, Issue 6, Pages 1023-+Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.hoc.2014.08.003
Keywords
Myeloproliferative neoplasms (MPN); Myelofibrosis; Polycythemia vera; Essential thrombocythemia; Hematopoietic stem cell transplantation; Ruxolitinib
Categories
Funding
- National Institutes of Health [HL036444]
Ask authors/readers for more resources
Myeloproliferative neoplasms (MPN) are clonal hematopoietic stem cell disorders. While some MPN patients have an indolent course, all are at risk of progressing to severe marrow failure or transforming into acute leukemia. Allogeneic hematopoietic cell transplantation (allo-HCT) is the only potential curative therapy. Major pre-transplant risk factors are disease stage of the MPN, the presence of comorbid conditions and the use of HLA non-identical donors. The development of reduced-intensity conditioning regimens has allowed for successful allo-HCT even for older patients and patients with comorbid conditions. The pre-transplant use of JAK2 inhibitors, which may be effective in down staging a patient's disease, may improve the outcomes following allo-HCT.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available